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clinical snippets
New Day for EBA
The organ-specific autoimmune 
disease epidermolysis bullosa 
acquisita (EBA) is characterized 
by chronic mucocutaneous 
subepidermal blistering caused 
by circulating antibodies 
directed against type VII 
collagen. Autoantibody binding 
and Fc-dependent engagement 
of inflammatory factors are 
required for disruption of the 
dermal–epidermal junction 
and consequent blistering. 
Although the pathogenesis 
of this relatively rare disease 
is becoming clear, therapy is 
difficult, and corticosteroids and 
other immunosuppressive drugs 
that are commonly employed 
subject patients to severe, and 
even life-threatening, adverse 
reactions. In response to the 
need for additional treatment 
modalities, Iwata and colleagues 
reported that treatment with 
soluble CD32, which binds 
to the immune complex to 
block FcγR binding on immune 
cells, effectively inhibited 
neutrophil activation and FcγR-
dependent dermal–epidermal 
separation in vitro and lessened 
clinical disease severity in 
EBA model mice, highlighting 
the beneficial effects of this 
factor on EBA. In another 
study, Hirose and colleagues 
provided evidence that 
intravenous immunoglobulin 
(IVIG) treatment ameliorated 
clinical disease severity and 
skin neutrophil infiltration 
in mice with induced EBA, 
via modulation of both the 
adaptive and the innate 
responses. Both soluble CD32 
and IVIG have been used 
as effective therapies for 
other autoimmune diseases, 
suggesting future clinical 
adaptation of these findings for 
EBA. See pages 768 and 916
Postnatal Clones
Large congenital mela-
nocytic nevi (lCMN) are 
benign tumors that result 
from neural crest–derived 
proliferation in the epider-
mis, dermis, or hypodermis, 
stemming predominantly 
from somatic NRAS muta-
tions. These nevi pose a 
risk for melanoma develop-
ment; however, the patho-
genesis is not well understood. Charbel and colleagues demonstrated that lCMN 
contain a population of cells that persist postnatally, are capable of self-renewal, and 
induce a nevus-like structure upon xenotransplantation in the presence of keratino-
cytes. The discovery of this cellular subpopulation, which also harbors NRAS muta-
tions, may explain the presence of secondary nevus resurgence following excision and 
the expansion of lCMN during childhood growth. See page 824
Multifunctional Medicine
The proton pump inhibitor omeprazole, 
which targets the ATPase ATP4a in the stom-
ach, is commonly used to treat gastroesopha-
geal reflux and acidity; however, Matsui and 
colleagues reported its efficacy in inhibition 
of melanogenesis in the UV-irradiated skin 
of human subjects. Studies in melanocytes 
and human skin equivalents suggested that 
omeprazole inhibits the ATP7A-dependent 
transport of copper to tyrosinase, which 
is critical for melanin production and enhances degradation of tyrosinase. Thus, the 
potential for repurposing omeprazole as a topical inhibitor of pigmentation is an inter-
esting implication of these findings. See page 834
Secrets of the Secretome
Patients with hypohidrotic ecto-
dermal dysplasia (ED) exhibit 
sparse scalp hair, abnormal 
teeth, and reduced sweating. 
Burian and colleagues used a 
quantitative proteomic approach 
to examine the abundance of 
proteins on the skin of healthy 
individuals and ED patients in 
order to determine whether altered secreted proteins influence ED clinical skin symp-
toms such as atopic dermatitis–like symptoms and recurrent skin infections. Proteins 
involved in tissue development and host defense were significantly reduced in the skin 
secretome of ED patients. Notably, dermicidin, which is an abundant antimicrobial 
peptide in eccrine sweat, was decreased in ED patients as in atopic dermatitis patients, 
supporting a role for sweat in skin immune defense. See page 759
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